Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
Curr Med Res Opin. 2011 Mar;27(3):633-41. doi: 10.1185/03007995.2010.551657. Epub 2011 Jan 18.
Recent guidelines recommend use of aspirin and either clopidogrel or prasugrel for at least 12 months following use of drug-eluting or bare metal stents in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). This study evaluated factors associated with clopidogrel use and adherence in ACS patients following PCI.
The US employer-based MarketScan commercial claims database was used to examine factors associated with clopidogrel use and adherence. Adherence was defined as a medication possession ratio of 80% or higher. Multivariate logistic regression analyses were conducted to identify factors associated with clopidogrel use and adherence and included patient demographics, comorbidities, and prior beta-blocker, statin, and angiotensin converting enzyme inhibitor (BSI) use as factors.
A total of 10,465 patients aged 18-65 years who met inclusion criteria were hospitalized for ACS and underwent PCI between 01/01/2005 and 12/31/2006. Overall, the rate of clopidogrel use was 92.8% for ACS-PCI patients and 66.8% of the clopidogrel users were adherent. Receiving PCI without stenting (Odds Ratio [OR] = 3.28), comorbid hypertension (OR = 1.50), diabetes (OR = 1.49), and atrial fibrillation (OR = 1.91) were associated with decreased filled prescriptions for clopidogrel. Younger age (OR = 0.83) and prior use of clopidogrel (OR = 0.54) or other BSI medications (OR = 0.44) were associated with increased use of clopidogrel (all p values < 0.05). Factors significantly associated with non-adherence of clopidogrel were prior use of clopidogrel (OR = 1.40), prior hospitalization (OR = 1.34), chronic pulmonary disease (OR = 1.31), PCI without stenting (OR = 1.32), diabetes (OR = 1.17), and younger age (OR = 1.29). Prior use of BSI medications (OR = 0.82) increased adherence to clopidogrel.
Prior use of clopidogrel, comorbid conditions such as diabetes and chronic pulmonary disease, prior hospitalization, PCI without stenting, and younger age had a negative impact on clopidogrel adherence. These findings may assist programs to improve thienopyridine compliance through a better understanding of patients' disease profiles and concomitant medication use.
近期指南建议,在急性冠脉综合征(ACS)患者行经皮冠状动脉介入治疗(PCI)后,对于使用药物洗脱支架或裸金属支架的患者,至少使用阿司匹林和氯吡格雷或普拉格雷 12 个月。本研究评估了 ACS 患者 PCI 后氯吡格雷使用和依从性的相关因素。
使用美国雇主基础的 MarketScan 商业索赔数据库,研究氯吡格雷使用和依从性的相关因素。依从性定义为药物利用率为 80%或更高。采用多变量逻辑回归分析确定与氯吡格雷使用和依从性相关的因素,包括患者人口统计学特征、合并症以及之前使用β受体阻滞剂、他汀类药物和血管紧张素转换酶抑制剂(BSI)的情况。
共纳入 10465 名年龄在 18-65 岁之间的患者,符合纳入标准,因 ACS 住院并于 2005 年 1 月 1 日至 2006 年 12 月 31 日期间接受 PCI。总体而言,ACS-PCI 患者氯吡格雷使用率为 92.8%,氯吡格雷使用者中 66.8%的患者依从性良好。未接受支架置入的 PCI(比值比[OR] = 3.28)、合并高血压(OR = 1.50)、糖尿病(OR = 1.49)和心房颤动(OR = 1.91)与氯吡格雷处方减少有关。年龄较小(OR = 0.83)和之前使用氯吡格雷(OR = 0.54)或其他 BSI 药物(OR = 0.44)与氯吡格雷使用率增加相关(所有 p 值均 < 0.05)。与氯吡格雷非依从性显著相关的因素包括之前使用氯吡格雷(OR = 1.40)、之前住院(OR = 1.34)、慢性肺病(OR = 1.31)、未接受支架置入的 PCI(OR = 1.32)、糖尿病(OR = 1.17)和年龄较小(OR = 1.29)。之前使用 BSI 药物(OR = 0.82)增加了氯吡格雷的依从性。
之前使用氯吡格雷、合并症如糖尿病和慢性肺病、之前住院、未接受支架置入的 PCI 以及年龄较小对氯吡格雷的依从性有负面影响。这些发现可能有助于通过更好地了解患者的疾病特征和同时使用的药物,来改善噻氯吡啶的依从性。